References
1. Lip, G.Y.H., The ABC pathway: an integrated approach to improve AF management. Nat Rev Cardiol, 2017. 14 (11): p. 627-628.
2. Kirchhof, P., et al., 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J, 2016. 37 (38): p. 2893-2962.
3. Al-Khatib, S.M., et al., Rate- and rhythm-control therapies in patients with atrial fibrillation: a systematic review. Ann Intern Med, 2014. 160 (11): p. 760-73.
4. Nikolaidou, T. and K.S. Channer, Chronic atrial fibrillation: a systematic review of medical heart rate control management. Postgrad Med J, 2009. 85 (1004): p. 303-12.
5. Tamariz, L.J. and E.B. Bass, Pharmacological rate control of atrial fibrillation. Cardiol Clin, 2004. 22 (1): p. 35-45.
6. Lafuente-Lafuente, C., et al., Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev, 2015(3): p. Cd005049.
7. Roy, D., et al., Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med, 2008. 358 (25): p. 2667-77.
8. Kirchhof, P., et al., Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised, open-label, blinded endpoint assessment trial. Lancet, 2012. 380 (9838): p. 238-46.
9. Cosedis Nielsen, J., et al., Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation. N Engl J Med, 2012.367 (17): p. 1587-95.
10. Wilber, D.J., et al., Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. Jama, 2010.303 (4): p. 333-40.
11. Arbelo, E., et al., The atrial fibrillation ablation pilot study: a European Survey on Methodology and results of catheter ablation for atrial fibrillation conducted by the European Heart Rhythm Association. Eur Heart J, 2014. 35 (22): p. 1466-78.
12. Wyse, D.G., et al., A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med, 2002.347 (23): p. 1825-33.
13. Van Gelder, I.C., et al., A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med, 2002. 347 (23): p. 1834-40.
14. Opolski, G., et al., Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study.Chest, 2004. 126 (2): p. 476-86.
15. Chatterjee, S., et al., Pharmacologic rate versus rhythm-control strategies in atrial fibrillation: an updated comprehensive review and meta-analysis. Pacing Clin Electrophysiol, 2013. 36 (1): p. 122-33.
16. Van Gelder, I.C., et al., Rate control in atrial fibrillation. Lancet, 2016. 388 (10046): p. 818-28.
17. Ionescu-Ittu, R., et al., Comparative effectiveness of rhythm control vs rate control drug treatment effect on mortality in patients with atrial fibrillation. Arch Intern Med, 2012. 172 (13): p. 997-1004.
18. Ogawa, S., et al., Optimal treatment strategy for patients with paroxysmal atrial fibrillation: J-RHYTHM Study. Circ J, 2009.73 (2): p. 242-8.
19. Hohnloser, S.H., et al., Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med, 2009.360 (7): p. 668-78.
20. Potpara, T.S. and G.Y. Lip, Patterns in atrial fibrillation management and ’real-world’ adherence to guidelines in the Balkan Region: an overview of the Balkan-atrial fibrillation survey. Eur Heart J, 2015. 36 (30): p. 1943-4.
21. Potpara, T.S., et al., Stroke prevention in atrial fibrillation and ’real world’ adherence to guidelines in the Balkan Region: The BALKAN-AF Survey. Sci Rep, 2016. 6 : p. 20432.
22. Lip, G.Y., et al., Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest, 2010. 137 (2): p. 263-72.
23. Pisters, R., et al., A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest, 2010. 138 (5): p. 1093-100.
24. Proietti, M., et al., Polypharmacy and major adverse events in atrial fibrillation: observations from the AFFIRM trial. Clin Res Cardiol, 2016. 105 (5): p. 412-20.
25. Purmah, Y., et al., Rate vs. rhythm control and adverse outcomes among European patients with atrial fibrillation. EP Europace, 2017. 20 (2): p. 243-252.
26. Noheria, A., et al., Rhythm Control Versus Rate Control and Clinical Outcomes in Patients With Atrial Fibrillation: Results From the ORBIT-AF Registry. JACC Clin Electrophysiol, 2016. 2 (2): p. 221-229.
27. Camm, A.J., et al., Real-life observations of clinical outcomes with rhythm- and rate-control therapies for atrial fibrillation RECORDAF (Registry on Cardiac Rhythm Disorders Assessing the Control of Atrial Fibrillation). J Am Coll Cardiol, 2011. 58 (5): p. 493-501.
28. Lip, G.Y., et al., Sex-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: a report from the Euro Observational Research Programme Pilot survey on Atrial Fibrillation. Europace, 2015. 17 (1): p. 24-31.
29. Reiffel, J.A., et al., Practice patterns among United States cardiologists for managing adults with atrial fibrillation (from the AFFECTS Registry). Am J Cardiol, 2010. 105 (8): p. 1122-9.
30. Nieuwlaat, R., et al., Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J, 2005. 26 (22): p. 2422-34.
31. Kirchhof, P., et al., Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events–European Registry in Atrial Fibrillation (PREFER in AF). Europace, 2014. 16 (1): p. 6-14.
32. Chen, S., et al., Rhythm control for patients with atrial fibrillation complicated with heart failure in the contemporary era of catheter ablation: a stratified pooled analysis of randomized data. Eur Heart J, 2019.
33. Nabauer, M., et al., The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace, 2009. 11 (4): p. 423-34.
34. Lip, G.Y., et al., A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. Europace, 2014. 16 (3): p. 308-19.
35. Rawles, J.M., M.J. Metcalfe, and K. Jennings, Time of occurrence, duration, and ventricular rate of paroxysmal atrial fibrillation: the effect of digoxin. Br Heart J, 1990. 63 (4): p. 225-7.
36. Lip, G.Y.H., et al., Prognosis and treatment of atrial fibrillation patients by European cardiologists: One Year Follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF Pilot registry). European Heart Journal, 2014. 35 (47): p. 3365-3376.
37. Lane, D.A. and G.Y. Lip, Patient’s values and preferences for stroke prevention in atrial fibrillation: balancing stroke and bleeding risk with oral anticoagulation , in Thromb Haemost . 2014: Germany. p. 381-3.
38. Proietti, M., et al., Improved Outcomes by Integrated Care of Anticoagulated Patients with Atrial Fibrillation Using the Simple ABC (Atrial Fibrillation Better Care) Pathway. Am J Med, 2018.131 (11): p. 1359-1366.e6.
39. Kirchhof, P., et al., Impact of the type of centre on management of AF patients: surprising evidence for differences in antithrombotic therapy decisions. Thromb Haemost, 2011.105 (6): p. 1010-23.
40. Jones, D.G., et al., A randomized trial to assess catheter ablation versus rate control in the management of persistent atrial fibrillation in heart failure. J Am Coll Cardiol, 2013.61 (18): p. 1894-903.
41. Khan, M.N., et al., Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. N Engl J Med, 2008.359 (17): p. 1778-85.
42. Fosbol, E.L., et al., Provider specialty and atrial fibrillation treatment strategies in United States community practice: findings from the ORBIT-AF registry. J Am Heart Assoc, 2013.2 (4): p. e000110.
43. Marrouche, N.F., et al., Catheter Ablation for Atrial Fibrillation with Heart Failure. N Engl J Med, 2018. 378 (5): p. 417-427.
44. Alboni, P., et al., Outpatient treatment of recent-onset atrial fibrillation with the ”pill-in-the-pocket” approach. N Engl J Med, 2004. 351 (23): p. 2384-91.
45. Boyd, C.M. and M. Fortin, Future of Multimorbidity Research: How Should Understanding of Multimorbidity Inform Health System Design?Public Health Reviews, 2010. 32 (2): p. 451-474.